Abbott Launches NeuroSphere Virtual Clinic For Remote Neurostim Programming
Executive Summary
The US FDA approved Abbott's system that allows physicians to communicate with patients and remotely program their neuromodulation device.
You may also be interested in...
CMS Extends Telehealth Coverage For 2023
The Medicare Physician Fee Schedule Final Rule for CY 2023 extended the coverage of telehealth services for 2023.
Abbott’s Next-Generation Spinal Cord Stimulator Gets FDA Nod
The newly approved Proclaim Plus system allows physicians to treat as many as six independent pain sites and choose the lowest-possible effective dose for each site.
Abbott’s Plan For DBS Depression Therapy Wins FDA’s Breakthrough Designation
Abbott continued St. Jude Medical’s prior research on deep brain stimulation for treating depression and has advanced the technology far enough that the US FDA now believes it could be a breakthrough treatment for treatment-resistant depression.